Skip to main content

Rabbit Recombinant Monoclonal Choline Acetyltransferase antibody - conjugated to Alexa Fluor® 568.

Be the first to review this product! Submit a review

Key facts

Isotype
IgG
Host species
Rabbit
Conjugation
Alexa Fluor® 568
Excitation/Emission
Ex: 578nm, Em: 603nm
Storage buffer

pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA

Form
Liquid
Clonality
Monoclonal

Immunogen

  • The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

Application
Target Binding Affinity
Reactivity
Expected
Dilution info
-
Notes

-

Application
Antibody Labelling
Reactivity
Expected
Dilution info
-
Notes

-

Target data

Function

Catalyzes the reversible synthesis of acetylcholine (ACh) from acetyl CoA and choline at cholinergic synapses.

Alternative names

Recommended products

Rabbit Recombinant Monoclonal Choline Acetyltransferase antibody - conjugated to Alexa Fluor® 568.

Key facts

Isotype
IgG
Conjugation
Alexa Fluor® 568
Excitation/Emission
Ex: 578nm, Em: 603nm
Form
Liquid
Clonality
Monoclonal
Immunogen
  • The exact immunogen used to generate this antibody is proprietary information.
Clone number
EPR16590
Purification technique
Affinity purification Protein A
Concentration
Loading...

Storage

Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle, Store in the dark

Notes

This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

Choline Acetyltransferase (ChAT) also known as EC 2.3.1.6 acts as the enzyme responsible for synthesizing the neurotransmitter acetylcholine. It catalyzes the transfer of an acetyl group from acetyl-CoA to choline to form acetylcholine. ChAT is a protein with an approximate mass of 70 kDa and is expressed in cholinergic neurons throughout the central and peripheral nervous systems. High expression is observed in regions such as the basal forebrain and neuromuscular junctions which are important for cholinergic signaling.

Biological function summary

The enzyme plays an important role in cholinergic conduction by producing acetylcholine which functions in synaptic transmission. It does not function as part of a larger complex but its activity directly influences cholinergic synapses. Choline acetyltransferase function ensures the synthesis and availability of acetylcholine for release into the synaptic cleft initiating muscle contraction and modulating activity in the central nervous system.

Pathways

Choline acetyltransferase is critical in pathways governing neurotransmitter release such as the cholinergic synapse pathway. It interacts functionally with other proteins within this pathway including acetylcholinesterase which breaks down acetylcholine in the synaptic cleft. This interaction ensures proper neurotransmitter regulation and recycling maintaining synapse function and communication within neuronal circuits.

Associated diseases and disorders

Alterations in choline acetyltransferase activity relate to neurological disorders including Alzheimer's disease and myasthenia gravis. In Alzheimer's disease reduced choline acetyltransferase function leads to decreased acetylcholine synthesis contributing to the cognitive decline observed in patients. In myasthenia gravis acetylcholine receptors are impaired but effective choline acetyltransferase activity is still necessary to manage neurotransmitter levels. A potential therapeutic angle involves targeting related proteins that exacerbate these conditions to support acetylcholine levels.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

0 product images

    Downloads

    Product protocols

    For this product, it's our understanding that no specific protocols are required. You can:

    Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

    For licensing inquiries, please contact partnerships@abcam.com